Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VCL-HB01 in symptomatic genital HSV-2 infection
NCT02837575Phase 2Completed
- Sponsor
- Vical Incorporated
- Start
- Sep 2016
- Primary completion
- Apr 2018
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of VCL-HB01 in genital herpes, sponsored by Vical Incorporated. Started Sep 2016; status: completed.
02
Drugs
VCL-HB01
03
Conditions
genital herpes
Beyond the preview
Go deeper on NCT02837575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02837575.